Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
314.00
-0.28 (-0.09%)
At close: Jan 30, 2026, 4:00 PM EST
318.02
+4.02 (1.28%)
After-hours: Jan 30, 2026, 7:38 PM EST
PRAX Employees
Praxis Precision Medicines had 116 employees as of December 31, 2024. The number of employees increased by 34 or 41.46% compared to the previous year.
Employees
116
Change (1Y)
34
Growth (1Y)
41.46%
Revenue / Employee
$64,336
Profits / Employee
-$2,353,759
Market Cap
8.71B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 116 | 34 | 41.46% | 116 | 0 |
| Dec 31, 2023 | 82 | -27 | -24.77% | 82 | 0 |
| Dec 31, 2022 | 109 | -30 | -21.58% | 109 | 0 |
| Dec 31, 2021 | 139 | 72 | 107.46% | 139 | 0 |
| Dec 31, 2020 | 67 | - | - | 67 | 0 |
| Sep 30, 2020 | 51 | - | - | 50 | 1 |
| Jun 30, 2020 | 37 | - | - | 37 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| BioMarin Pharmaceutical | 3,040 |
| Jazz Pharmaceuticals | 2,800 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 498 |
| Vaxcyte | 414 |
| Halozyme Therapeutics | 350 |
PRAX News
- 9 days ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 22 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - GlobeNewsWire
- 25 days ago - Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - GlobeNewsWire
- 25 days ago - Praxis Precision Medicines, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
- 4 weeks ago - Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor - GlobeNewsWire
- 7 weeks ago - Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 - GlobeNewsWire